secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001628280-22-027966
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics Q3 net loss widens to $32.0M; cash runway to end of 2024
------------------------------------------------------------------------

- Net loss $32.0M ($0.65/diluted share) vs $24.7M ($0.51) in Q3 2021; revenue $6.8M vs $8.5M.
- Cash, equivalents & marketable securities $366.0M at Sep 30, down from $451.5M at Dec 31, 2021; runway to end of 2024.
- Phase 1/2 trials for CFT7455 (IKZF1/3 degrader in MM/NHL) and CFT8634 (BRD9 in synovial sarcoma) advancing dose escalation.
- IND clearance for CFT1946 (BRAF-V600 degrader) in Sep; Phase 1/2 to initiate by year-end 2022.
- Upcoming milestones: CFT8919 (EGFR L858R) IND-enabling activities to complete by year-end 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828022027966/0001628280-22-027966-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828022027966/cccc-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-027966

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer